{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T14:42:17Z","timestamp":1779201737312,"version":"3.51.4"},"reference-count":15,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2023,11,21]]},"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:p>A woman in her 60s was admitted for refractory thrombocytopenia, initially presumed to be from immune thrombocytopenia (ITP). She was treated with the thrombopoietin receptor agonist (TPO-RA) avatrombopag, as well as prophylactic ciprofloxacin and fluconazole for neutropenia. She developed an anion gap metabolic acidosis with a significantly elevated lactate level peaking at 7.5\u2009mmol\/L. Other causes of lactic acidosis including hypovolaemia, sepsis, ischaemia and diabetic ketoacidosis were ruled out. Avatrombopag was discontinued, with quick resolution of the lactic acidosis. Fluconazole and ciprofloxacin were found to inhibit the metabolism of avatrombopag and were also discontinued. Worsening thrombocytopenia prompted a rechallenge with increased dose avatrombopag and severe lactic acidosis again developed, with subsequent quick resolution after drug discontinuation. We conclude that a dose-dependent lactic acidosis occurred with avatrombopag in this case. While other TPO-RAs including eltrombopag have been associated with lactic acidosis, to our knowledge, this is the first report of avatrombopag-induced lactic acidosis.<\/jats:p>","DOI":"10.1136\/bcr-2023-256463","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T19:16:01Z","timestamp":1701976561000},"page":"e256463","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Avatrombopag-induced lactic acidosis in a patient with severe thrombocytopenia"],"prefix":"10.1136","volume":"16","author":[{"given":"Amanda Marie","family":"Addiego","sequence":"first","affiliation":[{"name":"Washington University in St Louis, St Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samrah","family":"Razi","sequence":"additional","affiliation":[{"name":"Washington University in St Louis, St Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Li","sequence":"additional","affiliation":[{"name":"Washington University in St Louis, St Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,12,7]]},"reference":[{"key":"2025082703362629000_16.12.e256463.1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.212845"},{"key":"2025082703362629000_16.12.e256463.2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01553-7"},{"key":"2025082703362629000_16.12.e256463.3","unstructured":"Doptelet (avatrombopag) prescribing information. Durham, NC: Dova Pharmaceuticals Inc; 2019. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/210238s001lbl.pdf"},{"key":"2025082703362629000_16.12.e256463.4","unstructured":"Promacta (eltrombopag) prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2021. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/022291lbl.pdf"},{"key":"2025082703362629000_16.12.e256463.5","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/bjh.15574","article-title":"Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled phase 1 studies","volume":"183","author":"Kuter","year":"2018","journal-title":"Br J Haematol"},{"key":"2025082703362629000_16.12.e256463.6","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bjh.15573","article-title":"Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia","volume":"183","author":"Jurczak","year":"2018","journal-title":"Br J Haematol"},{"key":"2025082703362629000_16.12.e256463.7","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1097\/MPH.0000000000002300","article-title":"Eltrombopag-induced metabolic acidosis and hepatic encephalopathy in","volume":"44","author":"Hermann","year":"2022","journal-title":"J Pediatr Hematol Oncol"},{"key":"2025082703362629000_16.12.e256463.8","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/FTD.0000000000000522","article-title":"Eltrombopag-induced acute liver failure in a pediatric patient: a pharmacokinetic and pharmacogenetic analysis","volume":"40","author":"Marano","year":"2018","journal-title":"Ther Drug Monit"},{"key":"2025082703362629000_16.12.e256463.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1309483"},{"key":"2025082703362629000_16.12.e256463.10","unstructured":"Maxipime (Cefepime) prescribing information. Hospira Inc; 2016. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/050817s007lbl.pdf"},{"key":"2025082703362629000_16.12.e256463.11","unstructured":"Rituxan (Rituximab) prescribing information. Genentech; 2021. Available: https:\/\/www.gene.com\/download\/pdf\/rituxan_prescribing.pdf"},{"key":"2025082703362629000_16.12.e256463.12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa2109965","article-title":"Severe aplastic anemia working party of the European society for blood and marrow transplantation. Eltrombopag added to immunosuppression in severe aplastic anemia","volume":"386","author":"Peffault de Latour","year":"2022","journal-title":"N Engl J Med"},{"key":"2025082703362629000_16.12.e256463.13","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s40265-018-0949-8","article-title":"Avatrombopag: first global approval","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"key":"2025082703362629000_16.12.e256463.14","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1111\/bcp.13517","article-title":"Pharmacokinetic\/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs","volume":"84","author":"Nomoto","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"2025082703362629000_16.12.e256463.15","unstructured":"Center for Drug Evaluation and Research . Drug development and drug interactions | table of substrates, inhibitors and inducers. US Food and Drug Administration; 2022. Available: https:\/\/www.fda.gov\/drugs\/drug-interactionslabeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2023-256463","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:36:34Z","timestamp":1756290994000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2023-256463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":15,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12,7]]},"published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.1136\/bcr-2023-256463"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2023-256463","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12]]}}}